Information
-
Patent Application
-
20070191459
-
Publication Number
20070191459
-
Date Filed
February 12, 200717 years ago
-
Date Published
August 16, 200716 years ago
-
CPC
-
US Classifications
-
International Classifications
Abstract
The present invention is a method for the glucose related disorders and lipid related disorders comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel b benzo-heteroaryl sulfamide derivatives of formula (I) as herein defined. The present invention is further directed to methods of treatment comprising co-therapy with an anti-diabetic agent, and anti-lipid agent and/or an anti-obesity agent.
Claims
- 1. A method for a glucose related disorder comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula (I)
- 2. The method of claim 1 wherein
R1 is selected from the group consisting of hydrogen, halogen, trifluoromethyl, cyano and nitro;X-Y is selected from the group consisting of —S—CH—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;A is selected from the group consisting of —CH2— and —CH(CH3)—;R2 is selected from the group consisting of hydrogen and methyl;R3 and R4 are each independently selected from the group consisting of hydrogen, methyl and ethyl;or a pharmaceutically acceptable salt thereof.
- 3. The method of claim 2, wherein
R1 is selected from the group consisting of hydrogen, halogen, trifluoromethyl and cyano;X-Y is selected from the group consisting of —S—CH—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;A is selected from the group consisting of —CH2— and —CH(CH3)—;R2 is hydrogen;R3 and R4 are each independently selected from the group consisting of hydrogen and ethyl;or a pharmaceutically acceptable salt thereof.
- 4. The method of claim 3, wherein
R1 is selected from the group consisting of hydrogen, 5-chloro, 5-fluoro, 5-bromo, 4-bromo, 7-fluoro, 5-trifluoromethyl and 5-cyano;X-Y is selected from the group consisting of —S—CH—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;A is selected from the group consisting of —CH2— and —CH(CH3)—;R2 is hydrogen;R3 and R4 are each hydrogen; alternatively R3 is hydrogen and R4 is ethyl;or a pharmaceutically acceptable salt thereof.
- 5. The method of claim 1, wherein
R1 is selected from the group consisting of hydrogen, halogen, trifluoromethyl and cyano;X-Y is selected from the group consisting of —S—CH—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;A is selected from the group consisting of —CH2— and —CH(CH3)—;R2 is selected from the group consisting of hydrogen and methyl;R3 and R4 are taken together with the nitrogen atom to which they are bound to form a 5 to 7 membered, saturated, partially unsaturated or aromatic ring structure, optionally containing one to two additional heteroatoms independently selected from the group consisting of O, N and S;or a pharmaceutically acceptable salt thereof.
- 6. The method of claim 5, wherein
R1 is selected from the group consisting of hydrogen, halogen, trifluoromethyl and cyano;X-Y is selected from the group consisting of —S—CH—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;A is selected from the group consisting of —CH2— and —CH(CH3)—;R2 is selected from the group consisting of hydrogen and methyl;R3 and R4 are taken together with the nitrogen atom to which they are bound to form a 5 to 6 membered, saturated or aromatic ring structure, optionally containing one to two additional heteroatoms independently selected from the group consisting of O, N and S;or a pharmaceutically acceptable salt thereof.
- 7. The method of claim 6, wherein
R1 is hydrogen;X-Y is —S—CH—;A is —CH2—;R2 is hydrogen;R3 and R4 are taken together with the nitrogen atom to which they are bound to form a 5 membered ring structure selected from the group consisting of pyrrolidinyl and imidazolyl;or a pharmaceutically acceptable salt thereof.
- 8. The method of claim 2, wherein the compound of formula (I) is selected from the group consisting of
- 9. The method of claim 1, wherein the compound of formula (I) is selected from the group consisting of N-(benzo[b]thien-3-ylmethyl)-sulfamide; N-[(5-fluorobenzo[b]thien-3-yl)methyl]-sulfamide; and pharmaceutically acceptable salts thereof.
- 10. A method for a glucose related disorder comprising administering to a subject in need thereof, a therapeutically effective amount of a compound selected from the group consisting of N-(benzo[b]thien-3-ylmethyl)-sulfamide and pharmaceutically acceptable salts thereof.
- 11. The method of claim 1, wherein the glucose related disorder is selected from the group consisting of elevated glucose levels and Type II diabetes mellitus.
- 12. The method of claim 10, wherein the glucose related disorder is selected from the group consisting of elevated glucose levels and Type II diabetes mellitus.
- 13. A method for a lipid related disorder comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula (I)
- 14. The method of claim 13, wherein
R1 is selected from the group consisting of hydrogen, halogen, trifluoromethyl, cyano and nitro;X-Y is selected from the group consisting of —S—CH—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;A is selected from the group consisting of —CH2— and —CH(CH3)—;R2 is selected from the group consisting of hydrogen and methyl;R3 and R4 are each independently selected from the group consisting of hydrogen, methyl and ethyl;or a pharmaceutically acceptable salt thereof.
- 15. The method of claim 14, wherein
R1 is selected from the group consisting of hydrogen, halogen, trifluoromethyl and cyano;X-Y is selected from the group consisting of —S—CH—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;A is selected from the group consisting of —CH2— and —CH(CH3)—;R2 is hydrogen;R3 and R4 are each independently selected from the group consisting of hydrogen and ethyl;or a pharmaceutically acceptable salt thereof.
- 16. The method of claim 15, wherein
R1 is selected from the group consisting of hydrogen, 5-chloro, 5-fluoro, 5-bromo, 4-bromo, 7-fluoro, 5-trifluoromethyl and 5-cyano;X-Y is selected from the group consisting of —S—CH—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;A is selected from the group consisting of —CH2— and —CH(CH3)—;R2 is hydrogen;R3 and R4 are each hydrogen; alternatively R3 is hydrogen and R4 is ethyl;or a pharmaceutically acceptable salt thereof.
- 17. The method of claim 13, wherein
R1 is selected from the group consisting of hydrogen, halogen, trifluoromethyl and cyano;X-Y is selected from the group consisting of —S—CH—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;A is selected from the group consisting of —CH2— and —CH(CH3)—;R2 is selected from the group consisting of hydrogen and methyl;R3 and R4 are taken together with the nitrogen atom to which they are bound to form a 5 to 7 membered, saturated, partially unsaturated or aromatic ring structure, optionally containing one to two additional heteroatoms independently selected from the group consisting of O, N and S;or a pharmaceutically acceptable salt thereof.
- 18. The method of claim 17, wherein
R1 is selected from the group consisting of hydrogen, halogen, trifluoromethyl and cyano;X-Y is selected from the group consisting of —S—CH—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;A is selected from the group consisting of —CH2— and —CH(CH3)—;R2 is selected from the group consisting of hydrogen and methyl;R3 and R4 are taken together with the nitrogen atom to which they are bound to form a 5 to 6 membered, saturated or aromatic ring structure, optionally containing one to two additional heteroatoms independently selected from the group consisting of O, N and S;or a pharmaceutically acceptable salt thereof.
- 19. The method of claim 18, wherein
R1 is hydrogen;X-Y is —S—CH—;A is —CH2—;R2 is hydrogen;R3 and R4 are taken together with the nitrogen atom to which they are bound to form a 5 membered ring structure selected from the group consisting of pyrrolidinyl and imidazolyl;or a pharmaceutically acceptable salt thereof.
- 20. The method of claim 14, wherein the compound of formula (I) is selected from the group consisting of
- 21. The method of claim 13, wherein the compound of formula (I) is selected from the group consisting of N-(benzo[b]thien-3-ylmethyl)-sulfamide; N-[(5-fluorobenzo[b]thien-3-yl)methyl]-sulfamide; and pharmaceutically acceptable salts thereof.
- 22. A method for a lipid related disorder comprising administering to a subject in need thereof, a therapeutically effective amount of a compound selected from the group consisting of N-(benzo[b]thien-3-ylmethyl)-sulfamide and pharmaceutically acceptable salts thereof.
- 23. The method of claim 13, wherein the lipid related disorder is selected from the group consisting of elevated triglyceride levels and low HDL cholesterol levels.
- 24. The method of claim 22, wherein the lipid related disorder is selected from the group consisting of elevated triglyceride levels and low HDL cholesterol levels.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60773808 |
Feb 2006 |
US |